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Abstract
Background: Liver Receptor Homolog 1 (LRH-1, NR5A2) is an orphan nuclear receptor that is over-expressed in cancers in
tissues such as the breast, colon and pancreas. LRH-1 plays important roles in embryonic development, steroidogenesis and
cholesterol homeostasis. In tumor cells, LRH-1 induces proliferation and cell cycle progression. High LRH-1 expression is
demonstrated in breast cancers, positively correlating with ERa status and aromatase activity. LRH-1 dependent cellular
mechanisms in breast cancer epithelial cells are poorly defined. Hence in the present study we investigated the actions of
LRH-1 in estrogen receptor a (ERa) positive breast cancer cells.
Results: The study aimed to investigate LRH-1 dependent mechanisms that promote breast cancer proliferation. We
identified that LRH-1 regulated the expression of Growth Regulation by Estrogen in Breast Cancer 1 (GREB1) in MCF-7 and
MDA-MB-231 cells. Over-expression of LRH-1 increased GREB1 mRNA levels while knockdown of LRH-1 reduced its
expression. GREB1 is a well characterised ERa target gene, with three estrogen response elements (ERE) located on its
promoter. Chromatin immunoprecipitation studies provided evidence of the co-localisation of LRH-1 and ERa at all three
EREs. With electrophoretic mobility shift assays, we demonstrated direct binding of LRH-1 to EREs located on GREB1 and
Trefoil Factor 1 (TFF1, pS2) promoters. LRH-1 and ERa co-operatively activated transcription of ERE luciferase reporter
constructs suggesting an overlap in regulation of target genes in breast cancer cells. Over-expression of LRH-1 resulted in an
increase in cell proliferation. This effect was more pronounced with estradiol treatment. In the presence of ICI 182,780, an
ERa antagonist, LRH-1 still induced proliferation.
Conclusions: We conclude that in ER-positive breast cancer cells, LRH-1 promotes cell proliferation by enhancing ERa
mediated transcription of target genes such as GREB-1. Collectively these findings indicate the importance of LRH-1 in the
progression of hormone-dependent breast cancer and implicate LRH-1 as a potential avenue for drug development.
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Introduction
Exposure of breast tissue to circulating hormones is a key risk
factor in breast cancer incidence [1,2,3]. Therefore understanding
the mechanisms of hormonal actions is critical in progress towards
better treatment options. In this report we analysed the effect of
the orphan nuclear receptor NR5A2 (also termed Liver Receptor
Homolog-1, LRH-1) on the transcriptional regulation of Growth
Regulation by Estrogen in Breast Cancer (GREB1) and breast
cancer proliferation.
LRH-1 belongs to the NR5A subclass of nuclear receptors and
regulates gene transcription by binding as a monomer to an
extended nuclear receptor half-site, consensus YCAAGGYCR [4].
LRH-1 has well established roles in metabolic pathways involved
in bile acid synthesis [5,6] and reverse cholesterol transport [7,8].
It is highly expressed in the ovary where it is vital for the regulation
of steroidogenesis [9,10]. In embryonic tissue it causes the
differentiation of enterohepatic tissue [11,12] and pluripotency
in embryonic stem cells [13,14]. In addition LRH-1 has a role in
gastric, colon, pancreatic and breast cancers [15,16,17,18,19].
LRH-1 contributes to breast cancer development and progres-
sion through its ability to induce aromatase expression in cancer
associated stromal fibroblasts (CAFs) [17,18,20,21]. In postmen-
opausal breast cancers, aromatase in adipose is the major source of
mitogenic estrogen for growth of ER-positive breast tumors [22].
Aromatase activity is regulated primarily by transcriptional
changes of its gene CYP19A1, via various tissue-specific promoters.
Malignant breast epithelial cells secrete prostaglandin E2 (PGE2),
allowing increased LRH-1 expression and LRH-1 mediated
binding and transcriptional activation of aromatase promoter
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estrogen levels has a paracrine effect on neighbouring tumor cells
causing an elevation in LRH-1 expression via the direct binding of
ERa to its promoter [15]. LRH-1 can also regulate ERa
expression in breast cancer cell lines [24] providing evidence of
a positive feedback loop between LRH-1 and ERa within tumor
epithelial cells.
Although LRH-1 is not basally expressed in normal mammary
tissue, high expression has been demonstrated in the epithelial
compartment of both invasive ductal carcinoma and ductal
carcinoma in situ [15,17,18]. LRH-1 expression in human tumors
correlated with that of other genes involved in steroid synthesis,
including P450 side-chain cleavage, 3b-hydroxysteroid dehydro-
genase and the Steroidogenic Acute Regulatory protein, suggest-
ing that LRH-1 may influence in situ steroidogenesis in breast
cancer [17].
LRH-1 mediates the mitogenic effect of estrogen in breast
cancer cells since siRNA-mediated knockdown of LRH-1 inhibits
estrogen-induced MCF-7 cell proliferation [15]. Recently, we have
demonstrated that LRH-1 not only enables the migration and
invasion of breast cancer cell lines but also increases the
tumorigenic potential of the normal mammary epithelial cell line
MCF-10A [25].
To identify cellular pathways regulated by LRH-1 in breast
cancer epithelial cells, we performed microarrays to identify genes
which were transcriptionally regulated by LRH-1 in MCF-7 cells
which had LRH-1 over-expressed or knocked down (data not
shown). Interestingly one of the most significantly altered genes,
caused by modulation of LRH-1 expression, was Growth
Regulation by Estrogen in Breast Cancer (GREB1). Therefore
we aimed to elucidate mechanisms via which LRH-1 regulated
GREB1 transcription.
In the present study we demonstrate co-localisation of LRH-1
and ERa on three critical ERa response elements (EREs) on the
GREB1 promoter to activate transcription and cell proliferation.
LRH-1 bound directly to ERE sequences present on the
promoters of two well characterised, estrogen responsive genes
GREB1 and Trefoil Factor 1 (TFF2 or pS2). These findings
indicate that LRH-1 acts synergistically with ERa to induce
transcription of GREB1 and unravels a new mechanism of action
for LRH-1 in inducing cancer cell proliferation.
Results
Effects of LRH-1 on GREB1 expression in MCF-7 cells
MCF-7 cells were transfected with either an LRH-1 – specific
shRNA, a control shRNA, an expression vector encoding full-
length human LRH-1 cDNA or an empty expression vector.
Transfection with LRH-1 expression vector increased LRH-1
mRNA (12-fold) (Figure 1A) and protein expression (Figure 1B)
compared to vector only transfected cells. Transfection with an
expression plasmid encoding an LRH-1 – specific shRNA
reduced endogenous LRH-1 mRNA levels in MCF-7 cells by
approximately 5-fold compared to control shRNA – transfected
cells 24 h post transfection (Figure 1A). This was reflected in a
reduction in LRH- 1 protein by western blot analysis (Figure 1B).
Having confirmed over- and under- expression of LRH-1 in
MCF-7 cells, we next measured expression of GREB1, a gene
previously identified in microarray data sets as significantly
regulated by LRH-1 (data not shown). In LRH-1 over-expressing
cells, GREB1 expression was elevated 40-fold while in LRH-1
knock down cells, a 2-fold decrease in GREB1 expression was
observed (Figure 1C). These results correlated with the micro-
array findings.
GREB1 is a well characterised ERa target gene [26,27]. To
determine whether the increase in GREB1 expression could be
attributed to LRH-1 mediated changes in ERa expression, we
assessed protein expression by western blot. There was an
increase observed in ERa levels in LRH-1 over-expressing cells,
however the knockdown did not demonstrate a notable decrease
(Figure 1b).
Estrogen regulation of GREB1 transcription is mediated by 3
estrogen response elements (EREs) located in the distal and
proximal promoter regions [27] (Figure 2A). Analysis of the
GREB1 promoter sequence for LRH-1 nuclear receptor half sites
(LRHRE) containing the YCAAGGYCR motif (where Y is a
pyrimidine and R is a purine) identified three potential LRHRE
sites (Figure 2A). Interestingly these putative LRHREs were
located within the ERa nuclear receptor recognition sites (ERE)
found in the distal and proximal GREB1 promoter [27,28]. DNA
binding sites for ERa and LRH-1 demonstrated significant
sequence similarity (highlighted in Figure 2A), raising the
possibility that LRH-1 binding could occur within the palindromic
ERE sequence (PuGGTCAnnnTGACCPy) as depicted in
Figure 2A. This led to the hypothesis that LRH-1 could bind
directly to the ERE of these LRH-1/ERa target genes. To address
this hypothesis we examined the promoter regulation of GREB1 in
more detail.
LRH-1 is recruited with ERa on the GREB1 promoter
To demonstrate the interaction between LRH-1 and the EREs
at the GREB1 promoter, we used chromatin immunoprecipitation
(ChIP). We observed interaction of endogenous ERa and LRH-1
on these three ERE sites (Figure 2B) suggesting a direct role of
LRH-1 in transcriptional activation of GREB1. Following
estradiol treatment for 45 minutes, binding of both ERa and
LRH-1 to the three ERE motifs was increased (Figure 2B and 2C)
suggesting increased expression of LRH-1 and/or an estradiol-
enhanced recruitment with ERa to the promoter.
To assess whether ERa and LRH-1 simultaneously occupy the
GREB1 ERE, we used sequential chromatin immunoprecipita-
tion (SeqChIP) on chromatin obtained from MCF-7 cells
untreated with estradiol. The first SeqChIP experiment involved
ChIP with the LRH-1 antibody first, followed by a second ChIP
with the ERa antibody. PCR of the resulting DNA with primers
specific to ERE1 indicated co-occupancy of LRH-1 and ERa on
the proximal ERE under basal conditions (Figure 2D). As
validation, a second SeqChIP where ERa antibody was used in
the first ChIP, followed by LRH-1 antibody for a second ChIP, to
demonstrate the same result. Band intensity for the first ChIP (for
both LRH-1 and ERa antibodies) was greater, when compared to
results in Figure 2B, as the amount of chromatin introduced to
the reaction was altered. Collectively, these results demonstrate
the occupancy of both ERa and LRH-1 at the EREs located in
the GREB1 promoter region, and suggest a direct relationship
between LRH-1 and ERa in the regulation of GREB1 gene
expression.
LRH-1 binds directly to EREs on the GREB1 and pS2
promoters
As ChIP localises transcription factor binding only to the
general vicinity of target sequences within genomic DNA (200–
300 bp), we next confirmed that LRH-1 can bind directly to these
EREs using competition electrophoretic mobility shift assays
(EMSA, Figure 3A and 3B).
LRH-1 bound to all 3 GREB1 ERE probes and this LRH-1-
DNA complex was supershifted with addition of an LRH-1
antibody (Figure 3A). Furthermore displacement of binding of
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element (LRHRE) (from the well validated LRH-1 target gene
CYP19A1 PII promoter) was measured. Nuclear extracts form a
complex with the LRHRE probe from PII promoter and this
complex was supershifted in the presence of anti-LRH-1 antibody
but not the control immunoglobulin G (Figure 3B lanes 9 and 10).
Partial displacement of the LRH-1/LRHRE complex by ERE1
indicated a weak interaction (Figure 3, lane 5), while complete
displacement by ERE2 and ERE3 demonstrated strong binding to
these sequences (Figure 3, lanes 6 and 7). Furthermore LRH-1 also
interacted with the ERE sequence from the pS2 promoter
(Figure 3, lane 8). These results provide evidence for the direct
interaction of LRH-1 protein with the palindromic ERE motifs
located on the promoter regions of two well characterised ERa
target genes, GREB1 and pS2 (TFF1).
Transcriptional activation of ERE-containing luciferase
reporters by LRH-1 reflects a synergistic action with ERa
In order to determine if LRH-1 could increase transcription of
ERE-containing reporter constructs, expression plasmids encoding
either ERa or LRH-1 were transfected with a luciferase reporter
driven by two copies of either a consensus palindromic ERE
(26ERE), or the GREB1 ERE2 (GREB-ERE2). These reporter
constructs were chosen for their sequence variability. The
consensus ERE lacks the 59 nucleotides known to support LRH-
1 binding; while the GREB-ERE2 sequence contains the LRHRE
motif (Figure 2A). Hence the reporter with the consensus ERE
would not be expected to respond to LRH-1.
Transfection with ERa increased activities of both reporters,
and as expected, this induction was significantly enhanced by
10 nM estradiol treatment (Figures 4A and 4B). Transfection of
Figure 1. Modulation of LRH-1 expression in transcriptionally regulates GREB1. (a) Changes in LRH-1 mRNA and (b) protein levels in MCF-7
cells transfected with siRNA for LRH-1 (2LRH-1) or control; with pcDNA only or LRH-1-pcDNA (+LRH-1) constructs 24 h post transfection. (c) The
expression levels of GREB1 in response to LRH-1 knockdown (siRNA) and over-expression (+LRH-1). Data were presented as % fold change compared
to controls of the normalized expression levels, as mean 6 SD, n=3 separate experiments.
doi:10.1371/journal.pone.0031593.g001
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difference in 26ERE reporter activity (Figure 4A). However,
LRH-1 alone caused a slight increase on GREB-ERE2 promoter
activation but this was not altered by estradiol treatment
(Figure 4B). The difference in sequence of the ERE palindrome
between the two reporter constructs (with the GREB-ERE2
having a consensus LRHRE) could explain the small increment of
LRH-1 induced reporter activity and sequence specific affinity of
LRH-1 binding to EREs.
Cotransfection of ERa and LRH-1 caused a 2-fold increase in
activity of both reporter constructs (Figures 4A and B).
Interestingly with estradiol treatment there was a significant
increase in reporter activity when compared promoter activity
with ERa alone and estradiol treatment (Figures 4A and B). These
results suggest that LRH-1 may enhance ligand dependent activity
of ERa on transcriptional regulation of a subset of target genes.
Effects of LRH-1 on GREB-1 expression and estradiol-
dependent cell proliferation
We next determined the effects of LRH-1 on estrogen-
dependent cancer cell proliferation (Figure 5), and correlated cell
proliferation to changes in transcript levels of LRH-1, ERa and
GREB1 (Figure 6). LRH-1 over-expression in estrogen-depleted
cells resulted in a significant 2-fold increase in cell proliferation
(Figure 5). Estradiol treatment caused a 12-fold increase, while the
additive effect of LRH-1 and estradiol treatment caused a 37-fold
increase. In these cells, the combined increase LRH-1 and GREB1
expression positively correlates to proliferation.
Estradiol treatment caused a 6-fold increase in LRH-1
expression consistent with previous studies [15] (Figure 6A). In
the stably transfected, serum depleted cells, a 4-fold LRH-1 over-
expression compared to basal levels was observed. Interestingly,
the addition of 17b-estradiol in LRH-1 over-expressing MCF-7
cells caused a 24-fold increase in LRH-1 compared to basal
expression (Figure 6A). Similar expression patterns were observed
for GREB1 under these treatment conditions (Figure 5C).
Estradiol treatment induced a 4-fold increase in GREB1
expression, while a 32-fold increase was observed in estradiol
treated, LRH-1 over-expressing cells (Figure 5C). These results
show a clear positive correlation of LRH-1 and GREB1 transcript
expression. ERa transcript levels remained relatively unchanged in
response to the above treatment conditions. A two fold increase in
ERa transcript was observed in response to estradiol treatment
(Figure 5B). Over-expression of LRH-1 and estradiol treatment
did not demonstrate a cumulative increment in ERa mRNA, as
was observed for LRH-1 and GREB1 (Figure 5B). This lack of
change in ERa expression is in concordance with previous reports
[29]. Ligand activation of ERa and the increase in LRH-1
expression reflects the synergistic effects of LRH-1 and ERa
observed on reporter transactivation assays (Figures 4A and 4B).
These observations indicate the growth promoting role of LRH-1
and GREB-1 in an ERa dependent manner.
To examine the effect of LRH-1 on cell proliferation
independent of estrogen signalling we also treated cells with a
combination of estradiol and an ERa antagonist, ICI 182,780
(Figure 5). The presence of ICI 182,780 reduced estradiol-induced
Figure 2. LRH-1 binds to three ERE sites within the GREB1 promoter. (a) Location of regulatory EREs on the distal and proximal GREB1
promoter, highlighting (bold) sequence similarity of the LRH-1 nuclear receptor half site within the ERE palindrome. (b) Chromatin
immunoprecipitation (ChIP) showing occupancy of LRH-1 on the three EREs where ERa binds in the presence or absence of estradiol.
Immunoprecipitation was performed with anti-LRH-1 and ERa antibodies on chromatin isolated from MCF-7 cells treated with vehicle or 10 nM 17b-
estradiol for 45 mins. (c) The precipitated chromatin was analyzed by quantitative real-time PCR to demonstrate relative occupancy using the delta
delta Ct method. Data is normalised to 10% of input. Data is represented from 3 or more separate treatments and separate ChIP experiments. (d)
Sequential ChIP demonstrating co-localisation of ERa and LRH-1 on ERE1 of the GREB1 promoter. Figures are representative of 3 or more separate
ChIP experiments.
doi:10.1371/journal.pone.0031593.g002
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treated with estradiol and ICI 182,780, a 2 fold decreased was also
observed. However estradiol-mediated proliferation was signifi-
cantly higher in LRH-1 over-expressing, ICI 182,780 treated cells
compared to basal MCF7 cells (Figure 5). This implicates a role for
LRH-1 in mediating a positive effect on tumour cell proliferation
treated with ERa antagonists.
LRH-1 regulation of GREB1 expression occurs
independently of ERa expression
In the ER-negative breast cancer cell line MDA-MB-231 cells,
LRH-1 over-expression caused a significant, 26-fold increase in
GREB-1 expression (Figure 7C). Co-transfection with LRH-1 and
ERa with estradiol treatment demonstrated the synergistic effects
on GREB1 expression as observed in MCF7 cells. This data
demonstrates that LRH-1 is able to stimulate GREB1 expression
independent of ERa signalling.
Discussion
Little is known about the mechanisms of LRH-1 action in breast
tumors. LRH-1 is abnormally expressed in 45% of all breast
carcinomas and is positively correlated with tumor ER status [17].
Our finding suggests a novel association of LRH-1 and ERa in the
regulation of GREB1 transcription and cell proliferation.
The gene encoding GREB1 was first identified as one of the key
transcripts up-regulated in MCF-7 cells upon estradiol treatment
and thus named after its function [30]. Its expression is positively
correlated to ER-positive breast cancer in several clinical studies
[26,30, Rae, 2005 #406]. The role of GREB1 in cell proliferation
was demonstrated with the suppression of GREB1 with siRNA,
causing a significant reduction in cell proliferation [26]. Recently a
monoclonal antibody for GREB1 was created, allowing the
detection of a 216 kDa protein whose expression positively
correlated to ERa expression in breast cancer cell lines and tumor
samples, as well as to GREB1 mRNA transcript levels [31]. While
expression of GREB1 protein appears predominantly nuclear,
some cytoplasmic staining was also observed. GREB1 protein was
expressed in tumor epithelial cells and CAFs [31]. As commer-
cially available antibodies report variations in size of detected band
in western blots and variability in cell localisation, the current
study focussed on transcript expression analysis.
LRH-1 binds as a monomer to a specific sequence YCAAG-
GYCR. Analysis of DNA sequence motifs of ERE and LRH-1
nuclear receptor half site (LRHRE) indicated a sequence overlap
suggesting that LRH-1 could bind to EREs of the GREB1
promoter. Our studies show direct binding of LRH-1 to the EREs
of known ERa target genes GREB1 and pS2 (TFF1). We
demonstrate specificity of LRH-1 binding to all 3 ERE sequence
motifs with EMSAs. The recruitment of ERa and LRH-1 on distal
and proximal GREB1 promoter EREs by ChIP was also
demonstrated. By SeqChip experiments LRH-1 and ERa co-
occupancy under basal conditions, to ERE1, the ERE most
proximal to the start site was evident. ERa is thought to function
as an underlying core transcriptional scaffold for interaction with
other transcription factors such as the forkhead protein, FoxA1
Figure 3. LRH-1 binds to specific ERE sequences of the GREB1 and pS2 promoters. (a) EMSA showing binding of LRH-1 to the EREs present
in the GREB1 promoter. Radiolabeled ERE1-GREB1, ERE2-GREB1 and ERE3-GREB1 probes were incubated with in vitro translated LRH-1 protein. In vitro
translation of the empty vector was used as a negative control. Anti-LRH-1 antibody was added in addition to the probe and the LRH-1 protein to
indicate specificity of protein binding. (b) EMSA showing binding of LRH-1 to the EREs present in the GREB1 and pS2 promoters. Radiolabeled LRHRE
probe (containing the LRH-1 response element derived from the aromatase promoter), whole cell nuclear extracts infected with a LRH-1 viral
construct were incubated with various oligonucleotides (as listed in the figure) including unlabeled LRHRE, mutated LRHRE, ERE1-GREB1, ERE2-GREB1,
ERE3-GREB1 and ERE-pS2 which were added in 200 fold excess. Anti-LRH-1 antibody and IgG were also added in addition to the probe and the
nuclear extract to indicate specificity of protein binding.
doi:10.1371/journal.pone.0031593.g003
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stimuli including growth factors such as Epidermal Growth Factor
[32,33]. This scaffolding function is observed in the regulation of
GREB1 (located on chromosome 2) and pS2 (TFF1, located on
chromosome 21), where estrogen stimulated ERa DNA binding
resulted in the interaction or looping between the 2 chromosomal
regions and significant enhancement of gene expression [34]. Our
findings raise the possibility that LRH-1 may contribute to the
variable actions of ERa mediated transcription in breast cancer
cells.
In reporter transactivation assays, LRH-1 over-expression
caused a modest increase in GREB-ERE reporter activity and
no change on 26ERE activity. This discrepancy in response
reflects the importance of flanking sequences required for
selectivity of LRH-1 binding to EREs. The two distal EREs
located ,20 kb upstream from the GREB1 transcriptional start
site perform vital enhancer functions; ERa binding to these EREs
allows chromatin looping and interaction with the proximal ERE
to initiate GREB1 transcription [28]. Therefore the use of two
copies of a single GREB1 ERE may not be sufficient to
demonstrate the impact of LRH-1 and ERa on GREB1
transcription. However, the finding of most interest in the current
study is the co-operative effect of ERa and LRH-1 expression in
estradiol-treated conditions. This additive effect is observed
consistently in mRNA expression analysis, promoter assays and
ChIP experiments suggesting that LRH-1 may be associating with
the ligand-activated ERa within a transcriptional complex at the
EREs of GREB1 promoter.
Figure 4. LRH-1 acts synergistically with ERa to activate ERE containing promoters. Transcriptional activation of (a) 26ERE and (b) GREB-
ERE2 luciferase reporters by ERa and LRH-1 with vehicle (veh) or 10 nM 17b-estradiol (E2). Estrogen-deprived MCF-7 cells were over expressed with
LRH-1 or ERa alone, or in combination with the appropriate reporter construct. Cells were treated with 17b-estradiol for 16 h prior to luciferase
assays. Data is presented as mean+SE, n=3 separate experiments, treatments in triplicate per experiment. *P,0.05, *P,0.01, ***P,0.001 compared
to vehicle control unless indicated by reference line.
doi:10.1371/journal.pone.0031593.g004
Figure 5. LRH-1 induces cell proliferation in 17b-estradiol and
ICI 182,780 treated cells. Cell proliferation was measured in pcDNA
alone transfected, estrogen-deprived MCF-7 cells (control) or LRH-1
over-expressing (+LRH-1) MCF-7 cells treated with vehicle, 10 nM 17b-
estradiol (E2) or 10 nM 17b-estradiol and 1 nM ICI 182,780, an ERa
antagonist for 5 days. Data is presented as mean+SEM, n=3 separate
experiments, triplicate treatments per experiment, ***P,0.001 com-
pared to control transfected cells; a,b P,0.001 compared to vehicle
control.
doi:10.1371/journal.pone.0031593.g005
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[15,16,25,35]. In breast cancer cells it enhances cell proliferation
as a downstream effector of estradiol treatment [15]. In the present
study, basal and LRH-1 over-expressing MCF-7 cells when treated
with estradiol demonstrated a dramatic increase in GREB1
expression, and this correlated with increases in cell proliferation.
The pattern of LRH-1 mRNA mirrored that of GREB1 while
ERa mRNA levels were relatively unchanged under these
treatment conditions. The expression data indicates that the
activation of ERa, combined with the increase in the constitutively
active LRH-1 expression, correlates to elevated GREB1 levels.
These transcriptional changes are reflected in increased cell
Figure 6. Synergistic effects of LRH-1 and 17b-estradiol treatment on GREB1 expression. Quantitation of (a) LRH-1, (b) GREB1 and (c) ERa
mRNA expression in estrogen-deprived MCF-7 cells (control) or LRH-1 over-expressing (+LRH-1) MCF-7 cells treated with vehicle (veh) or 10 nM 17b-
estradiol (E2) for 16 h. Data is presented as mean+SE, n=3 separate experiments, triplicate treatments per experiment, **P,0.01, ***P,0.001
compared to vehicle control.
doi:10.1371/journal.pone.0031593.g006
Figure 7. LRH-1 regulation of GREB1 expression in ER negative breast cancer cells. MDA-MB-231 cells were transfected with empty vector
(C) or expression vectors for LRH-1 alone (L), ERa alone (E) or both LRH-1 and ERa (L+E). Cells were treated with vehicle or 10 nM 17b-estradiol (E2) for
16 h. Quantitation of (a) LRH-1, (b) ERa and (c) GREB1 mRNA expression. Data is presented as mean+SE, n=3 separate experiments, ***P,0.001
compared to vehicle control.
doi:10.1371/journal.pone.0031593.g007
LRH-1 Regulates GREB1 Expression in Breast Cancer
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31593proliferation in LRH-1 over-expressing, estradiol-treated MCF-7
cells. In ER-positive breast cancers, GREB1 expression is
correlated with high circulating estradiol levels [36]. In addition,
LRH-1 expression is regulated by estradiol, reflected by the
positive correlation of its expression in ER-positive tumors [15,17].
In MCF-7 treated with the ERa inhibitor ICI 182,780, the
presence of LRH-1 maintained increased proliferation indicating
an ERa independent effect on cell proliferation previously not
reported. This implicates that the presence of LRH-1 in tumours
treated with selective ER modulators may account for estrogen –
independent proliferation. Hence the regulation of GREB1
expression by LRH-1 identifies a novel mechanism for tumor cell
proliferation.
Sun et al (2007) showed that the three EREs of the GREB1 locus
exhibit different degrees of ERa, coactivator, and polymerase II
binding and suggested that different transcriptional regulators may
be involved in modulating the ERa driven transcription from the 3
different GREB1 core promoters. Thus LRH-1 may be acting as a
coregulator for some of these GREB1 core promoters, and it may
possess different binding affinities to the EREs. We tested this
hypothesis and demonstrated that LRH-1 was able to regulate
ERa target genes such as GREB1 in ER-negative cancer cells such
as MDA-MB-231 cells. LRH-1 also stimulated GREB1 expression
significantly, however this effect was lower than that induced by
ERa. The synergist actions of LRH-1 and ERa appeared to have
the most potent effect on GREB1 expression and proliferation. It
is a distinct possibility however that other ERa target genes may
be transcriptionally regulated by LRH-1 in ER-negative tumor
cells.
Another effect LRH-1 may confer is to maintain the expression
of ERa target genes for longer durations post estradiol treatment.
GREB1 expression rapidly induced within 2 h of estradiol
treatment and maintained over a 48 h period [26,30]. Could
LRH-1 be a mechanism for the maintenance of ERa target gene
expression? Assessing transcript levels of GREB1 in LRH-1 over-
expressing and basal MCF-7 cells as varying time points post
estradiol treatment would answer this question.
The synergistic increase in cell proliferation in LRH-1 over-
expressing, estradiol treated cells could also reflect increased LRH-
1 activity in addition to an increase in expression. While LRH-1 is
constitutively active, it requires coactivators such as SRC1 and
SRC3 to further activate its functions [37,38]. As estrogen is
needed to increase levels of SRC1 and SRC3 and has been shown
to associate with the three GREB1 EREs [27], this is likely to
cause activation of both ERa and LRH-1 at the transcriptional
complexes as the proximal and distal promoters.
In summary, our findings provide a molecular mechanism for
LRH-1 induced cell proliferation in ER-positive breast cancer
cells; via the up-regulation of GREB1 expression. LRH-1 was able
to induce GREB1 expression independent of ERa expression
suggesting an estrogen independent effect on proliferation. This is
the first evidence of LRH-1 binding to a subset of ERE
palindrome motifs, as observed in GREB1 and pS2 gene
promoters. In addition LRH-1 can colocalise with ERa (basally
and in response to estradiol treatment) on proximal and distal
promoter regions critical for the activation of GREB1 expression.
As these proximal and distal regions connect via chromatin
looping and may suggest a possible role for LRH-1 in aiding this
transcriptional process. Whether LRH-1 partners with ERa as a
heterodimer and whether LRH-1 can regulate ERa target genes in
ER-negative tumor cells remains to be investigated.
Approximately 60% of premenopausal and 75% of postmen-
opausal breast cancer patients have ER-positive tumors. LRH-1
expression is positively correlated with tumor ERa status and here
we demonstrate a co-operative effect of LRH-1 and ERa on
GREB1 expression and cell proliferation. As some of the most
successful therapies for breast cancer target the inhibition of ERa
actions or of aromatase activity, the blockade of LRH-1 action in
ER- positive tumors may provide further efficacy to current
treatment regimes.
Materials and Methods
Plasmids
The human LRH-1 expression vector was generated as
described previously [25]. The LRH-1 shRNA vector was
constructed by cloning a double-stranded oligonucleotide targeting
the appropriate sequence (GGATCCATCTTCCTGGTTA cor-
responding to nucleotides 1425-1407 of Genbank NM_205860)
into pGeneclip hMGFP (Promega). The use of these constructs has
been previously verified [25].
Cell culture and transfection
All cells used were obtained from ATCC and grown in the
recommended culture media and conditions. MCF-7 cells were
cultured in DMEM (GIBCO) supplemented with 10% FBS,
50 U/ml penicillin and 50 mg/ml streptomycin at 37uCi n5 %
CO2 (all reagents obtained from Invitrogen). For LRH-1
knockdown, cells were transfected with either pGeneclip
hMGFP-LRH-1 or pGeneclip hMGFP encoding a scrambled
shRNA sequence as negative control (SABiosciences). For over-
expression, cells were co-transfected with either pcDNA3.1+ or
pcDNA3.1+LRH-1, and pGFP. Cells were transfected using the
Nucleofector Kit V (Amaxa Biosystems), according to the
manufacturer’s instructions. GFP-positive cells were collected by
fluorescence-activated cell sorting (FACS) 48 hours after transfec-
tion and replated or protein and RNA extracted as required.
MDA-MB-231 cells were transfected with pcDNA containing
constructs for LRH-1 and ERa using the Nucleofector Kit V as
decribed previously (Chand et al., 2010).
17b-estradiol (Sigma) treatments were performed in MCF-7-tet
on cells that stably expressed the pTRE-LRH-1 construct. This
allowed inducible treatment of LRH-1 with treatment with 1 ug/
ml doxycyclin (Sigma). These cells were deprived of estradiol in
phenol red free culture media supplemented with 5% charcoal
stripped calf serum for 72 h prior to treatments with vehicle
(ethanol) or 10 nM 17b-estradiol (Sigma) for 16 h. Doxycyclin
treatment was performed for the same duration as vehicle or
estradiol treatments to induce LRH-1 expression. Cells were then
used for cell proliferation assays or RNA extracted for further
studies.
RNA extraction and quantitative real time PCR (qPCR)
Total RNA was extracted from cultured cells using the RNeasy
kit (Qiagen), treated with DNaseI (Ambion), and quantified using a
NanoDrop 1000 Spectrophotometer. First strand cDNA synthesis
was accomplished using AMV reverse transcriptase (Promega) and
random hexamers. For qPCR, cDNAs were diluted 1:10 in water
and amplified using SYBR Green chemistry on the LightCycler
system (Roche), as previously described (Clyne et al. 2002). Primer
sequences are outlined in Figure S1. Fold changes in expression of
each gene were calculated using the delta delta Ct method [39]
using 18S as the internal control.
Western blot analysis
Protein extraction and western immunoblots for LRH-1 and b-
tubulin were performed as described previously [25]. Protein
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and Odyssey 3.0 software (Licor Biosciences).
Chromatin immunopreciptiation
MCF-7 cells were cultured for 3 days in phenol red free medium
containing 5% CSS and then treated for 45 mins with vehicle
(ethanol) or 10 nM 17-bestradiol (Sigma). Cells were fixed 10 min
in PBS containing 1% formaldehyde, after which the reaction was
stopped with addition of glycine. Chromatin was isolated and
sheared according to protocols described previously [23]. Ten mlo f
sheared chromatin (300–500 bp) was collected as input and
immunoprecipitation performed overnight with no antibody, 4 mg
IgG or antibodies raised against human ERa (Santa Cruz) or
LRH-1 (Abcam) separately or sequentially. Immunoprecipitated
chromatin was eluted and reverse cross-linked according ChIP-IT
Express (Active Motif) manufacturer’s guide. Primers used for the
amplification of ChIP chromatin are outlined in Figure S1. The
precipitated chromatin was analyzed by quantitative real-time
PCR to demonstrate relative occupancy using the delta delta Ct
method. Data is normalised to 10% of input. Data is represented
from 3 or more separate treatments and separate ChIP
experiments.
Electrophoretic mobility shift assays (EMSA)
Forward and reverse oligonucleotides (0.1 mg/ml) containing the
consensus LRH-1 binding site (LRHRE) of aromatase promoter II
(LRHRE sequences: Figure S1) were added in equal amounts and
used as probes. Additional probes used included a mutated
LRHRE sequence; GREB1 ERE1, GREB1 ERE2, GREB1
ERE3 and ERE of pS2 (see Figure S1 for all probe sequences).
The concentrations of the forward and reverse oligonucleotides
were 1 mg/ml. Probes were labelled and purified as described
previously [40]. For competition experiments, 200-fold molar
excess of mutant SFRE, GREB1 ERE, GREB1 ERE2, GREB1
ERE3 and ERE of pS2 annealed double-stranded oligonucleotides
were included just before adding labelled probe to the reaction
buffer (56gel shift buffer, 0.5 mg/ml Poly dI.dC, 10 mg/ml BSA
and 100 mM DTT). Protein was obtained eitherfrom whole cell
extracts of sf9 insect cells infected with baculoviruses containing
the cDNA of the human LRH-1; or in vitro translated empty
expression vector (pcDNA3.1) or LRH-1 cDNA containing
pcDNA vector construct. In vitro translation reactions were
performed using thePromega TNT Quick Coupled Translation
System (Roche). Mouse IgG (negative control) or anti-LRH-1
antibody (Abcam) were incubated on ice for 20 mins with whole
cell extracts to demonstrate specificity of interactions. DNA-
protein complexes were separated by electrophoresis on a 4%
polyacrylamide gel in 0. 56TBE buffer at 4uC.
Luciferase reporter assays
HEK293 cells were plated into 48-well plates and transfected
with 10 ng hLRH-1 pcDNA and or hERa pCDNA construct with
200 ng 26ERE-luc (donated by Dr S Chu) or GREB-ERE2-
constructs. The 26ERE-luc reporter contains the palindromic
ERE sequence: AGGTCACAGTGACCTgagctcAGGTCACAG-
TGACCT [41]. To construct the GREB-ERE reporter construct,
complementary oligonucleotides encoding the GREB1 ERE2 (59-
39: sense: TCTCAAAAGGTCATCATGACCTTATTGT, and
antisense: ACAATAAGGTCATGATGACCTTTTGAGA) were
annealed and ligated to form concatamers using T4 kinase and T4
ligase. DNA corresponding to 2 copies of the ERE sequence were
purified, ligated into pGEMT-Easy, sequenced to confirm correct
orientation, and then subcloned into the luciferase reporter vector
pGL3basic. For transfections, DNA amounts were equalised by
the addition of the empty vector (pcDNA3.1) construct and a 1:3
DNA: Lipofectamine ratio used for the transfection as specified by
manufacturers (Invitrogen). Cells were maintained in media
supplemented with 5% charcoal stripped serum overnight after
which cells were treated overnight with 10 nM 17 b-estradiol
(Sigma).
Cell proliferation assay
Transfected and treated cells, as detailed previously, were
washed with PBS, subjected to trypsinisation. Cells were
suspended in media supplemented with 10% FCS and Trypan
Blue stain was added to the cell suspension. Viable cell number
was quantitated using the Countess Automated Cell Counter
according to the manufacturer’s instructions (Invitrogen).
Statistical analysis
All data are reported as mean 6 SE for three or more
experiments. Statistical analyses for experiments comparing two
groups were performed by two-tailed Student’s independent t test
using GraphPad Prism 5.0 (GraphPad, La Jolla, CA, USA) and a P
value of ,0.05 was considered statistically significant.
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